U.S., June 26 -- ClinicalTrials.gov registry received information related to the study (NCT07035197) titled 'Facilitators and Barriers to Eptinezumab Administration in Thailand' on June 03.
Brief Summary: This research study is designed as a longitudinal prospective descriptive study using mixed-method data collection. Eptinezumab, an anti-calcitonin gene-related peptide monoclonal antibody (anti-CGRP mAb), is administered by intravenous (IV) infusion every 3 months as preventive medication for individuals with migraine who have been diagnosed based on theInternational Classification of Headache Disorders, 3rd edition (ICHD-3) by headache specialist neurologists. The goal of this study is to understand the real-life experiences of people w...